Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma

Si-Yu Wang

Status and phase

Completed

Phase 2

Conditions

Lung Cancer

Treatments

Drug: Neoadjuvant Bevacizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT01588704

wsy002 (Other Identifier)

GASTO1001

Details and patient eligibility

About

The prognosis of patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) is poor. Chemoradiotherapy is the main treatment modality for this disease. The newer drug regimens can be expected to improve survival in this subset of NSCLC patients. Modern targeted therapies have enhanced the outcomes of lung cancer treatment, especially for advanced NSCLC. Among the targeted approaches for the inhibition of angiogenesis is bevacizumab, a monoclonal antibody that represses vascular endothelial growth factor (VEGF). Bevacizumab in combination with platinum-based chemotherapy used as neoadjuvant chemotherapy may change the previous treatment modality. It allows some lung cancer patients to be downstaged to surgery rather than radiotherapy. Thus, survival of these patients may be improved.

Full description

This trial investigates the role of neoadjuvant pemetrexed, carboplatin and bevacizumab in unresectable, locally advanced lung adenocarcinoma.

Enrollment

42 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically confirmed unresectable, locally advanced (III A (bulky N2), III B) lung adenocarcinoma
No previous chemotherapy, radiotherapy, surgery or biological therapy for lung cancer
Adequate organ and bone marrow function

Exclusion criteria

Prior chemotherapy or radiation therapy for NSCLC
Prior treatment with bevacizumab or other agents specifically targeting vascular endothelial growth factor (VEGF)
Patients with known hypersensitivity to other recombinant human antibodies
History of stroke or transient ischemic attack (TIA).
History of myocardial infarction or unstable angina within the past 12 months.
Other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), symptomatic diverticulitis, or active uncontrolled infection.
Women who are pregnant or breast-feeding